Dr Elisa Martelletti recently attended the Oxford-Harrington Rare Disease Centre Symposium, which brought together experts from academia, industry, healthcare, and patient advocacy to discuss advances in rare disease research and treatment development.
Sessions included “Therapy Development for Rare Neurological Diseases”, “Biopharma Industry Perspectives on Translation, Policy and Patient Access to Rare Disease Medicines”, and “Global Delivery and Equitable Access to N-of-1 Therapies”, alongside discussions on advances in gene and oligonucleotide therapies for rare diseases. The programme also featured an update from Dr Rusty Clayton, Chief Medical Officer at Larimar Therapeutics, on the development of nomlabofusp for Friedreich’s ataxia.
The meeting also provided an opportunity to connect with researchers, clinicians, and industry leaders working across rare diseases and to explore potential collaborations that could benefit the DRPLA community.
Oxford-Harrington Rare Disease Centre Symposium 2026
